Replies to post #233327 on Biotech Values

[RNsidersbuying]

FDA spells out guidelines for approving Covid-19 vaccines

By SARAH OWERMOHLE

06/30/2020 12:34 PM EDT

Updated: 06/30/2020 04:02 PM EDT

The FDA on Tuesday released final guidance laying out its standards for approving coronavirus vaccines, requiring that any vaccine candidate be at least 50 percent more effective than a placebo.

The agency also left open the possibility it would issue an emergency use authorization for a vaccine, but it said making that decision before the completion of large, randomized clinical trials could make it harder to determine a vaccine's effectiveness.

https://www.politico.com/news/2020/06/30/fda-guidelines-coronavirus-vaccines-345527

[RNsidersbuying]

NBIO .10 - several officers accumulating:

Nascent CFO Lowell Holden stated, "I believe the Company has continued to be undervalued and is now positioned to add significant value. The IND clearance by the FDA, along with the pending clinical trials, gives me confidence in its growth."

https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-Officers-Convert-Liability-to-Stock-in-the-Company?id=267054

[RNsidersbuying]

NBIO .12 - SAN DIEGO, CA / ACCESSWIRE / July 28, 2020...Alison Patteson, an assistant professor of physics at Syracuse University, will test to see if Pritumumab has the potential to block SARS-CoV-2 (SARS2), the virus responsible for COVID-19, from entering cells. According to Patteson, research shows that SARS2 may be traveling into cells by way of a receptor known as cell-surface vimentin (CSV). This ia a protein found on the cell surface, similar to vimentin, which is a key internal structural protein present in many cell types. Vimentin is known for its cage-like structure which protects the cell against damage.

https://finance.yahoo.com/news/nascent-biotech-announces-collaboration-syracuse-120000355.html